Longevity Biotechnology Association

Today marks the beginning of the 11th Annual Aging Research & Drug Discovery Meeting (ARDD), hosted for the second consecutive year by the University of Copenhagen (Københavns Universitet). This year, the event has reached full capacity, including all sponsorship tiers—an achievement that the LBA is proud to be a part of, both as a sponsor and as a board member supporting the event and organizing side activities. Over the next five days, more than 180 leading experts from around the world will share their insights. These speakers represent the forefront of pharmaceutical and biotech industries, focusing on areas such as metabolism, neurodegenerative conditions, muscle wasting, and aging-related diseases. Attendees can look forward to the latest advances in understanding the molecular, cellular, and organismal foundations of aging. #ARDD2024 #AgingResearch #DrugDiscovery #LongevityScience #AgingBreakthroughs

I’m delighted to welcome Neurodon and Russell Dahl to the Longevity Biotechnology Association.

The LBA is beyond excited to share with you our newest member and collaborating partner! Welcome Russell Dahl, CEO of Neurodon Corporation. Neurodon began as a team of scientists building upon an established yet not fully explored approach to disease: addressing cellular stress and calcium imbalance in cells. Research has shown that cellular stress and calcium imbalance are at the root of a wide range of diseases. For years, the team has focused on how activating a calcium pump called SERCA in the cell can restore calcium balance and reverse cellular stress. Neurodon's breakthrough therapeutics are now under preclinical development for diseases such as diabetes, Alzheimer’s, Parkinson’s, Duchenne muscular dystrophy, and other rare diseases. They have formed impressive partnerships to help achieve their vision of changing the lives of patients suffering from debilitating diseases. To learn more about Neurodon: https://lnkd.in/enJ_bcSn #CellularStress #CalciumImbalance #SERCA #DiseaseResearch #Diabetes #Alzheimers #Parkinsons #DuchenneMuscularDystrophy #RareDiseases #BreakthroughTherapeutics #MedicalResearch #PreclinicalDevelopment

Largest proteomics study to date! Delays in diagnosing many diseases stem from a lack of objective biomarkers. A study involving 41,931 individuals from the UK Biobank integrated plasma protein measurements with clinical information to predict the 10-year incidence of 218 diseases. Protein-based models outperformed traditional clinical models for 67 diseases and those using additional assay data for 52 diseases. Validation in the EPIC-Norfolk study confirmed these findings. These results suggest that plasma protein signatures can provide valuable predictions for both common and rare diseases.

Can a #biological #age test keep you healthy? The Buck shared pros and cons of these tests with the Today Show.

LBA member and Genflow Biosciences CEO Dr. Eric Leire shared updates on their progress and future plans. Key points include: -Secured funding to advance programs, particularly lead candidate GF-1002, with guidance from the FDA and European Agency. -Focus on global reach, aligning efforts in Europe and the US. -Promising results in clinical trials for dogs with sirtuin 6 (SIRT6) variants, which could expedite human trials. -Collaboration with Exothera S.A. for cost-effective large-scale production of SIRT6 variants. -Upcoming focus on clinical trials for MASH and advancing the dog study, with potential veterinary pharmaceutical collaborations.

Great insights from LBA member and BioAge CEO, Kristen Fortney! During the three-day Aspen Ideas Health event, Kristen provided fantastic perspectives on longevity science and how it’s reshaping the future of human health.

The full recording of the "AI For Longevity Drug Discovery: Breakthrough and Challenges" webinar is now available. On June 18, 2024, the American Federation for Aging Research (AFAR) hosted a webinar for scientific and entrepreneurial professionals, offering insights into AI's real-world applications in drug discovery, along with its challenges and breakthroughs. The discussion, coordinated by AFAR Board Member Sergey Young (CEO of the Longevity Vision Fund), was moderated by Longevity Biotechnology Association member Dr. Kristen Fortney of BioAge and featured experts Dr. Hanadie Yousef of Juvena Therapeutics, Dr. Alex Zhavoronkov of Insilico Medicine, and Dr. Ben Blue of Ora Biomedical, Inc. Watch: https://lnkd.in/g4rtbBpQ #DrugDiscovery #BiotechTherapeutics #AgingResearch #AFAR #LongevityVisionFund #BioAge #JuvenaTherapeutics #InsilicoMedicine #OraBiomedical

The LBA is proud to partner with XPRIZE Healthspan, with LBA co-founder Dr. Nir Barzilai serving on the Advisory Board. Traditional medicine treats symptoms as they appear, extending life without proactively improving health, often leading to poor quality of life and economic challenges in later years. This competition aims to foster scientific breakthroughs in creating proactive therapeutics that reduce chronic age-related diseases, increase healthspan, and enhance quality of life. Successful trials could revolutionize our approach to aging, establish guidelines for healthy aging, and reduce healthcare costs. This initiative seeks to democratize health and unlock the full potential of aging.

Exciting news! The American Federation for Aging Research is hosting a free webinar on June 18 titled “AI Drug Discovery for Longevity.” Join biotech leaders as they discuss the breakthroughs and challenges that AI brings to Longevity Drug Discovery. The event will be held online and is expected to attract a diverse audience, including scientists, students, enthusiasts, donors, and AI experts. Confirmed speakers include Alex Zhavoronkov from Insilico Medicine, Hanadie Yousef from Juvena Therapeutics, and Mitchell Lee from Ora Biomedical, with Kristen Fortney from BioAge as the moderator. Mark your calendars for Tuesday, June 18, from 1 PM to 2 PM ET. Learn more and RSVP here: https://ow.ly/TF9q50RYQjr